Objective
Staphylococcus aureus is a commensal of the human skin and nares, and a major cause of skin, and soft tissue as well as invasive infections. Bacterial pathogenicity results from a complex interplay of virulence factors with regulatory systems that respond to multiple external signals from the host environment and the bacterial population. Currently no vaccine against S. aureus is available. Novartis Vaccines and Diagnostics (NVD) has employed the reverse vaccinology approach to identify a list of novel antigens which are now under further analysis for inclusion in a vaccine. RESTAVAC will investigate the regulatory mechanisms involved in controlling expression of these vaccine antigen candidates. By analysing the temporal expression of novel antigens and characterised reference virulence factors, through reporter fusions, in various in vitro, ex vivo and animal models, RESTAVAC will uncover regulatory responses to environmental stimuli, diverse niches or disease settings as well as the molecular mechanisms involved in their fine-tuning. This will aid in predicting the efficacy of the candidate proteins as vaccine antigens and contribute to understanding their roles in the pathogenesis of the bacterium. Secondly, analysis of global gene expression profiles in ex vivo and animal models will greatly assist in identifying critical genes important for the different disease outcomes and the regulatory networks that may be involved. Such analysis will help to unravel the complex interactions between S. aureus and its host environmental niches during disease development. And thirdly, comparative analysis of reporter gene expression in both HA- and CA- isolates from geographic, temporal and sequence-type diverse origins along with genome-wide expression profiling will shed light on fundamental differences of this emerging group of pathogens as well as understanding the patterns of gene expression of the vaccine antigen genes across diverse staphylococcal disease isolates.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciences biological sciences microbiology bacteriology
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2012-IEF
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
53100 Siena
Italy
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.